NeoGenomics Company Leadership
| NEO Stock | USD 17.90 0.27 1.49% |
NeoGenomics' insiders are aggressively selling. The analysis of insiders' sentiment of trading NeoGenomics stock suggests that virtually all insiders are panicking at this time. NeoGenomics employs about 2.1 K people. The company is managed by 21 executives with a total tenure of roughly 18 years, averaging almost 0.0 years of service per executive, having 100.0 employees per reported executive.
| William Bonello President Vice President of Strategy - Corporate Development and Investor Relations |
| Kathryn McKenzie President Principal Accounting Officer, Vice President - Finance |
NeoGenomics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-11-15 | Alicia C Olivo | Disposed 5175 @ 15.36 | View | ||
| 2024-02-15 | Alicia C Olivo | Disposed 2587 @ 14.96 | View |
Monitoring NeoGenomics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
NeoGenomics |
NeoGenomics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with NeoGenomics' future performance. Based on our forecasts, it is anticipated that NeoGenomics will maintain a workforce of about 2100 employees by January 2025.NeoGenomics Management Team Effectiveness
The company has Return on Asset of (0.0276) % which means that on every $100 spent on assets, it lost $0.0276. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0838) %, meaning that it generated no profit with money invested by stockholders. NeoGenomics' management efficiency ratios could be used to measure how well NeoGenomics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 12th of December 2024, Return On Tangible Assets is likely to drop to -0.12. In addition to that, Return On Capital Employed is likely to grow to -0.06. At this time, NeoGenomics' Fixed Asset Turnover is very stable compared to the past year.As of the 12th of December 2024, Common Stock Shares Outstanding is likely to grow to about 131.8 M, though Net Loss is likely to grow to (123.3 M).
NeoGenomics Workforce Comparison
NeoGenomics is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 2,860. NeoGenomics totals roughly 2,100 in number of employees claiming about 73% of equities under Health Care industry.
NeoGenomics Profit Margins
The company has Net Profit Margin of (0.12) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.08) %, which entails that for every $100 of revenue, it lost $0.08.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.28 | 0.4134 |
|
|
NeoGenomics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NeoGenomics insiders, such as employees or executives, is commonly permitted as long as it does not rely on NeoGenomics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, NeoGenomics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 1.3077 | 17 | 13 | 314,181 | 114,615 |
| 2024-03-01 | 6.0 | 18 | 3 | 1,175,556 | 15,822 |
| 2023-09-01 | 6.0 | 18 | 3 | 177,201 | 1,694 |
| 2023-06-01 | 3.1667 | 19 | 6 | 1,054,493 | 55,996 |
| 2023-03-01 | 1.0 | 2 | 2 | 309,838 | 997.00 |
| 2022-12-01 | 2.6667 | 8 | 3 | 671,468 | 56,291 |
| 2022-09-01 | 0.75 | 3 | 4 | 744,974 | 221,240 |
| 2022-06-01 | 7.0 | 21 | 3 | 777,429 | 9,118 |
| 2022-03-01 | 1.4 | 14 | 10 | 1,114,371 | 18,672 |
| 2021-12-01 | 2.1111 | 19 | 9 | 498,016 | 185,180 |
| 2021-09-01 | 1.1429 | 8 | 7 | 187,475 | 44,547 |
| 2021-06-01 | 1.8125 | 29 | 16 | 493,013 | 525,862 |
| 2021-03-01 | 1.2778 | 23 | 18 | 446,800 | 170,496 |
| 2020-12-01 | 0.4333 | 13 | 30 | 797,004 | 1,607,149 |
| 2020-09-01 | 0.4231 | 11 | 26 | 245,729 | 902,266 |
| 2020-06-01 | 6.3333 | 19 | 3 | 63,741 | 37,735 |
| 2020-03-01 | 1.2857 | 18 | 14 | 771,561 | 638,098 |
| 2019-12-01 | 0.5385 | 14 | 26 | 1,133,209 | 1,923,681 |
| 2019-09-01 | 0.2917 | 7 | 24 | 47,793 | 408,277 |
| 2019-06-01 | 1.1765 | 20 | 17 | 424,349 | 881,161 |
| 2019-03-01 | 1.0769 | 28 | 26 | 964,443 | 1,154,905 |
| 2018-12-01 | 0.4348 | 10 | 23 | 458,233 | 15,910,515 |
| 2018-09-01 | 0.4 | 2 | 5 | 243,471 | 225,404 |
| 2018-06-01 | 0.7 | 21 | 30 | 360,163 | 8,164,913 |
| 2018-03-01 | 5.0 | 10 | 2 | 2,067,500 | 14,000 |
| 2017-12-01 | 1.0 | 2 | 2 | 289,000 | 45,000 |
| 2017-09-01 | 1.0 | 5 | 5 | 55,833 | 58,333 |
| 2017-06-01 | 2.7692 | 36 | 13 | 2,026,948 | 371,083 |
| 2017-03-01 | 0.5556 | 5 | 9 | 236,133 | 561,598 |
| 2016-12-01 | 0.4 | 2 | 5 | 13,334 | 8,115,001 |
| 2016-09-01 | 1.4545 | 16 | 11 | 650,430 | 1,255,300 |
| 2016-06-01 | 1.5 | 21 | 14 | 2,147,594 | 1,695,412 |
| 2016-03-01 | 1.1667 | 7 | 6 | 1,232,007 | 1,632,000 |
| 2015-12-01 | 2.0 | 8 | 4 | 128,386 | 410,000 |
| 2015-06-01 | 3.75 | 15 | 4 | 1,163,320 | 0.00 |
| 2014-12-01 | 2.0 | 16 | 8 | 724,175 | 220,282 |
| 2014-09-01 | 2.0 | 2 | 1 | 800,000 | 0.00 |
| 2014-06-01 | 1.0 | 6 | 6 | 237,000 | 377,500 |
| 2013-12-01 | 0.2857 | 4 | 14 | 240,000 | 239,894 |
| 2013-06-01 | 0.3333 | 2 | 6 | 100,000 | 140,000 |
| 2012-12-01 | 0.1667 | 1 | 6 | 188,571 | 4,321,128 |
| 2012-06-01 | 1.375 | 11 | 8 | 585,288 | 215,186 |
| 2012-03-01 | 0.3333 | 1 | 3 | 800,000 | 70,055 |
| 2011-12-01 | 0.1429 | 1 | 7 | 3,000 | 48,000 |
| 2011-09-01 | 5.0 | 5 | 1 | 8,956 | 40,000 |
| 2011-06-01 | 0.3684 | 7 | 19 | 57,710 | 100,000 |
NeoGenomics Notable Stakeholders
A NeoGenomics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as NeoGenomics often face trade-offs trying to please all of them. NeoGenomics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting NeoGenomics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| William Bonello | Vice President of Strategy - Corporate Development and Investor Relations | Profile | |
| Warren Stone | President Division | Profile | |
| Vishal Sikri | President Diagnostics | Profile | |
| JD Esq | President Informatics | Profile | |
| Kathryn McKenzie | Principal Accounting Officer, Vice President - Finance | Profile | |
| Fernando LpezDaz | Director Science | Profile | |
| Facmg MBA | Pres Officer | Profile | |
| George Cardoza | Pres Operations | Profile | |
| Gary Passman | Chief Officer | Profile | |
| Alicia Olivo | General Development | Profile | |
| Ali Olivio | Gen Sec | Profile | |
| Cynthia Dieter | Chief Officer | Profile | |
| Christopher BSc | CEO Director | Profile | |
| Charlie Eidson | Director Devel | Profile | |
| Kendra Sweeney | Vice Communications | Profile | |
| Derek MD | Chief Officer | Profile | |
| Hutan JD | Chief Officer | Profile | |
| Gregory Aunan | Senior Officer | Profile | |
| John Mooney | Chief Officer | Profile | |
| Greg Sparks | Chief Officer | Profile | |
| Jeffrey MBA | Chief Officer | Profile |
About NeoGenomics Management Performance
The success or failure of an entity such as NeoGenomics often depends on how effective the management is. NeoGenomics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of NeoGenomics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the NeoGenomics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.11) | (0.12) | |
| Return On Capital Employed | (0.07) | (0.06) | |
| Return On Assets | (0.05) | (0.05) | |
| Return On Equity | (0.09) | (0.09) |
NeoGenomics Workforce Analysis
Traditionally, organizations such as NeoGenomics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare NeoGenomics within its industry.NeoGenomics Manpower Efficiency
Return on NeoGenomics Manpower
| Revenue Per Employee | 281.7K | |
| Revenue Per Executive | 28.2M | |
| Net Loss Per Employee | 41.9K | |
| Net Loss Per Executive | 4.2M | |
| Working Capital Per Employee | 238.3K | |
| Working Capital Per Executive | 23.8M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.306 | Earnings Share (0.61) | Revenue Per Share 5.098 | Quarterly Revenue Growth 0.104 | Return On Assets (0.03) |
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.